Advertisement


Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Advertisement